WilmerHale Named Among Top Three Life Sciences Law Firms

WilmerHale Named Among Top Three Life Sciences Law Firms

Firm News

Related Solutions

Providing comprehensive solutions for the acquisition, enforcement and protection of IP.
Clients trust us to protect their most important intellectual property matters.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.
Helping clients launch their businesses and transform their innovative ideas into successful companies.
For companies in the life sciences sphere, licensing intellectual property and establishing strategic alliances are critical. WilmerHale’s experienced licensing lawyers shepherd biotech, pharmaceutical, healthcare and medical device clients of all sizes through the complex transactions that make their businesses possible, including a broad range of licensing, collaboration, strategic alliance and joint venture agreements. Our attorneys also excel at brokering manufacturing and supply agreements, contract research and development agreements, distribution and commercialization services agreements, and material transfer and confidentiality agreements. They also frequently represent life sciences clients as they license patents—often the foundations of their companies—from, and sponsor research at, leading academic institutions across the United States and Europe. Backed not only by their own experience but also the deep well of knowledge possessed by the firm’s patent, tax, antitrust and EU competition lawyers, our transactional attorneys are ready to handle even the most multifaceted matters. Our team helps clients protect their innovations, forge strategic alliances, and successfully navigate a complex, dynamic industry.
We leverage technical knowledge, business acumen and legal experience to structure, prepare and negotiate innovative and effective technology-related agreements.
WilmerHale’s corporate lawyers have a long history of experience with cross-border deals involving mergers and acquisitions, public offerings and capital markets, venture capital, joint ventures and other transactions.

WilmerHale has been named among the top three Best Life Sciences Law Firms for 2016 in the inaugural Life Science Index. Litigation finance firm Lake Whillans launched the Index in collaboration with research partners at Breaking Media—the publisher of leading industry sites MedCity News and Above the Law. The Index identifies which law firms are the most active and relevant for life science companies. Along with the overall rankings, WilmerHale was selected as the top firm in the patent category. 

“Entrepreneurs in the life sciences space face a myriad of challenges—regulatory hurdles, funding, product development, clinical trials, intellectual property matters and much more,” said Lee Drucker, principal at Lake Whillans, as reported by Above the Law. “Having the right legal counsel as a partner can easily make or break a business venture. We created this index with the goal of helping startups, as well as more established companies, identify the top law firms with deep experience in every aspect of the life sciences life cycle.”

In addition to collecting data in three practice categories—corporate, intellectual property and regulatory—the index rankings incorporate information on firms' work with startup companies, as well as the firms' thought leadership efforts. The methodology behind the Index was designed to reflect a holistic view of the role of a law firm throughout the life cycle of a life sciences company: from inception through clinical trials. 

Visit lakewhillans.com to view the complete index and to learn about the research process.

 

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.

I Accept Cancel